Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Free Cash Flow (2016 - 2025)

Conmed's Free Cash Flow history spans 16 years, with the latest figure at $41.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 4.9% year-over-year to $41.2 million; the TTM value through Dec 2025 reached $150.9 million, down 1.95%, while the annual FY2025 figure was $150.9 million, 1.95% down from the prior year.
  • Free Cash Flow reached $41.2 million in Q4 2025 per CNMD's latest filing, down from $48.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $51.5 million in Q4 2023 to a low of -$17.3 million in Q4 2022.
  • Average Free Cash Flow over 5 years is $26.0 million, with a median of $28.8 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 2046.76% in 2021, then crashed 156.46% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $30.6 million in 2021, then tumbled by 156.46% to -$17.3 million in 2022, then soared by 398.37% to $51.5 million in 2023, then dropped by 23.75% to $39.3 million in 2024, then grew by 4.9% to $41.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Free Cash Flow are $41.2 million (Q4 2025), $48.5 million (Q3 2025), and $23.4 million (Q2 2025).